Short Interest in FibroGen, Inc. (NASDAQ:FGEN) Decreases By 11.8%

FibroGen, Inc. (NASDAQ:FGEN) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 3,440,000 shares, a decline of 11.8% from the November 15th total of 3,900,000 shares. Based on an average trading volume of 1,180,000 shares, the days-to-cover ratio is currently 2.9 days.

Hedge Funds Weigh In On FibroGen

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC boosted its holdings in shares of FibroGen by 34.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after buying an additional 860,854 shares in the last quarter. AQR Capital Management LLC raised its position in FibroGen by 139.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 769,586 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in FibroGen during the 3rd quarter worth $307,000. XTX Topco Ltd purchased a new position in FibroGen during the 2nd quarter worth $424,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 280,161 shares in the last quarter. 72.71% of the stock is currently owned by institutional investors.

FibroGen Stock Up 7.1 %

Shares of FGEN traded up $0.02 during midday trading on Tuesday, hitting $0.35. The company’s stock had a trading volume of 1,422,219 shares, compared to its average volume of 2,117,156. FibroGen has a one year low of $0.18 and a one year high of $2.93. The stock has a market capitalization of $35.08 million, a price-to-earnings ratio of -0.26 and a beta of 0.82. The company’s fifty day simple moving average is $0.35 and its two-hundred day simple moving average is $0.58.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the previous year, the business posted ($0.52) earnings per share. On average, research analysts predict that FibroGen will post -0.86 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on FGEN. StockNews.com initiated coverage on shares of FibroGen in a research report on Monday. They issued a “hold” rating for the company. William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.